A new class of drugs, microbiome therapeutics are gaining prominence. The obvious initial therapeutic area for gut microbiome modalities is in infectious diseases as evidenced by the recent approvals. There are three approved microbiome-based drugs. Seres Therapeutics’ VOWST and Ferring Pharmaceuticals’ REBYOTA have been approved by the US FDA. BiomeBank’s Biomictra has received approval from Therapeutic Goods Administration (TGA) in Australia. All three are approved for Clostridium difficile bacteria infection.
According to GlobalData’s Pharma Intelligence Centre, there are currently 388 microbiome therapeutics under development. The most targeted therapy areas for these agents are gastrointestinal conditions, with 106 agents, followed by infectious diseases with 74 agents, and oncology with 65 agents.
Cancer
Researchers and companies are actively exploring the potential of microbiome-based therapies in oncology. Various studies evaluating microbiome-based therapies to enhance the efficacy of cancer immunotherapy are currently underway.
In 2022, South Korean firm Genome & Company collaborated with American pharma giant Merck, for a phase 2 trial involving its cancer blockbuster drug Keytruda. The trial aimed to evaluate the efficacy of Genome & Company’s lead product, GEN-001, in treating biliary tract cancer patients. Genome & Company’s lead pipeline GEN001 is said to be the first candidate for an immune-oncology microbiome therapeutic in Korea. Currently, clinical studies (Phase I/Ib) targeting multiple solid cancer patients (non-small cell lung cancer, head and neck cancer, urothelial cancer) are being conducted in the US and Korea.
This story is from the BioSpectrum Asia June 2023 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the BioSpectrum Asia June 2023 edition of BioSpectrum Asia.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Ushering Fourth Industrial Revolution in Telangana
Taking advantage of the 21st edition of BioAsia 2024 at the Hyderabad International Convention Centre (HICC) in Madhapur, the Government of Telangana, a southern state in India, leveraged the confluence of the global platform to spearhead initiatives aimed at propelling the state into the forefront of the Fourth Industrial Revolution (C4IR).
How Indian Biotech Investments are on a Doubling Spree
A latest report by Ankur Capital provides a closer look at the investments made in biotechnology in the last decade in the country.
"AI will be integrally involved in not only the diagnosis of cancer but also in determining the prognosis and best therapeutic option”
South Korea-based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry.
"Because of its specificity and selectivity, ADCS have the potential to reduce adverse side effects and improve patient survival"
Japan-headquartered Daiichi Sankyo, the global healthcare company, launched its subsidiary Daiichi Sankyo Singapore Pte. Ltd. to bridge unmet needs in oncology.
Can Test, Treat, Track Beat Malaria?
Malaria has long been a major public health concern in the Asia Pacific region, particularly in South East Asia (SEA) affecting millions of people.
Engineering CAR T cell sharpshooters
Approved CAR T-cell therapies have shown remarkable results in patients with certain types of blood cancers.
Addressing Challenges in Cell Therapy Manufacturing
Even with significant advancements, there are still anumber of issues with cell therapy manufacturing that need to be resolved as production grows.
"We anticipate India will adopt decentralised models for managing CGTs, ensuring closer proximity between patients and treatment facilities"
Cell and gene therapy (CGT) expert from Germany, Miltenyi Biotec has recently announced its entry into the Indian market to provide researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.
Addressing Accessibility and Affordability of CELL & GENE THERAPIES
Cell and gene therapies (CGT) are one of the hottest sectors in the pharmaceutical industry.
Korea designs sweat resistant wearable robot sensor
New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.